X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA ASTRAZENECA PHARMA NATCO PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 33.8 93.7 36.1% View Chart
P/BV x 17.2 13.3 129.2% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 NATCO PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
ASTRAZENECA PHARMA
Mar-14
NATCO PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs8771,285 68.2%   
Low Rs424634 66.8%   
Sales per share (Unadj.) Rs223.4189.6 117.9%  
Earnings per share (Unadj.) Rs31.1-0.2 -15,259.1%  
Cash flow per share (Unadj.) Rs40.33.8 1,047.6%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.568.6 319.8%  
Shares outstanding (eoy) m33.0725.00 132.3%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.95.1 57.5%   
Avg P/E ratio x20.9-4,712.7 -0.4%  
P/CF ratio (eoy) x16.1249.6 6.5%  
Price / Book Value ratio x3.014.0 21.2%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,50423,988 89.6%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m1,1281,605 70.3%   
Avg. sales/employee Rs ThNM3,040.2-  
Avg. wages/employee Rs ThNM1,029.2-  
Avg. net profit/employee Rs ThNM-3.3-  
INCOME DATA
Net Sales Rs m7,3894,740 155.9%  
Other income Rs m16792 181.4%   
Total revenues Rs m7,5564,832 156.4%   
Gross profit Rs m1,793-130 -1,381.6%  
Depreciation Rs m304101 300.8%   
Interest Rs m3660-   
Profit before tax Rs m1,290-139 -928.6%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m3095 6,064.8%   
Profit after tax Rs m1,027-5 -20,184.7%  
Gross profit margin %24.3-2.7 -886.2%  
Effective tax rate %23.9-3.7 -653.1%   
Net profit margin %13.9-0.1 -12,947.7%  
BALANCE SHEET DATA
Current assets Rs m3,6812,726 135.0%   
Current liabilities Rs m3,1232,435 128.2%   
Net working cap to sales %7.66.1 123.0%  
Current ratio x1.21.1 105.3%  
Inventory Days Days8974 121.3%  
Debtors Days Days5941 144.0%  
Net fixed assets Rs m7,6851,035 742.3%   
Share capital Rs m33150 661.4%   
"Free" reserves Rs m6,670942 707.7%   
Net worth Rs m7,2591,716 423.0%   
Long term debt Rs m9550-   
Total assets Rs m11,9574,156 287.7%  
Interest coverage x4.5NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.1 54.2%   
Return on assets %11.7-0.1 -9,516.3%  
Return on equity %14.2-0.3 -4,771.7%  
Return on capital %20.70-  
Exports to sales %39.45.7 690.3%   
Imports to sales %5.76.5 88.2%   
Exports (fob) Rs m2,908270 1,076.2%   
Imports (cif) Rs m421306 137.5%   
Fx inflow Rs m3,445375 919.8%   
Fx outflow Rs m703470 149.5%   
Net fx Rs m2,743-96 -2,870.3%   
CASH FLOW
From Operations Rs m1,440-8 -17,781.5%  
From Investments Rs m-1,089-146 747.6%  
From Financial Activity Rs m-353862 -40.9%  
Net Cashflow Rs m-1709 -0.2%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 75.0 2.0%  
Indian inst/Mut Fund % 7.8 0.3 2,613.3%  
FIIs % 16.6 15.7 105.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 9.1 285.7%  
Shareholders   25,395 12,856 197.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   WYETH LTD  IPCA LABS  ALKEM LABORATORIES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS